KSQ Therapeutics, a biotechnology company co-founded by a member of Forbes' 2017 30 Under 30 list, has raised $76 million and appointed a high-profile chief executive. Casey AtkinsThe new round was led by Flagship Pioneering; Polaris Partners, ARCH Venture Partners, and Alexandria Equities also participated. KSQ is also announcing that it has found a CEO: David Meeker, the former top executive at Sanofi's Genzyme rare disease unit. "The angle for this company is it has learned to do it at scale and with a high level of precision. Meeker believes the new technology could provide a solution to the waste that is driving up the cost of developing new medicines.

Source: Forbes October 02, 2017 11:01 UTC